Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
- About Dovepress
Open access peer-reviewed scientific and medical journals.
- Open Access
Dove Medical Press is now a member of the Open Access Initiative
- An Author's Guide
A guide to help authors get their paper published.
Support Open Access and Dove Press
Promotional Article Monitoring - further details
- Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Clinical features and treatment of maturity onset diabetes of the young (MODY)
(7239) Total Article Views
Authors: Gardner DS,Tai ES
Published Date May 2012 Volume 2012:5 Pages 101 - 108
|Received:||24 February 2012|
|Accepted:||01 March 2012|
|Published:||01 May 2012|
1Department of Endocrinology, Singapore General Hospital, 2Department of Endocrinology, National University Hospital, Singapore
Abstract: Maturity onset diabetes of the young (MODY) is a heterogeneous group of disorders that result in ß-cell dysfunction. It is rare, accounting for just 1%–2% of all diabetes. It is often misdiagnosed as type 1 or type 2 diabetes, as it is often difficult to distinguish MODY from these two forms. However, diagnosis allows appropriate individualized care, depending on the genetic etiology, and allows prognostication in family members. In this review, we discuss features of the common causes of MODY, as well as the treatment and diagnosis of MODY.
Keywords: type 1 diabetes, type 2 diabetes, HNF1A, HNF4A, HNF1B, GCK
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter
Readers of this article also read:
- ACC 2014
We will attend the 2014 American College of Cardiology Scientific Session and Expo (ACC) on March 29-31, 2014. Stop by booth 3217 to talk with us.
"You do a tremendous job!!" Ruben Restrepo, University of Texas Health Science Center, San Antonio.
- Randomized, double-blind, placebo-controlled, linear dose, crossover study to evaluate the efficacy and safety of a green coffee bean extract in overweight subjects
- Comparison with ancestral diets suggests dense acellular carbohydrates promote an inflammatory microbiota, and may be the primary dietary cause of leptin resistance and obesity
- The economic impact of obesity in the United States
- Alogliptin: a new addition to the class of DPP-4 inhibitors